China-Australia Free Trade Agreement – The Healthcare Opportunity

China-Australia Free Trade Agreement – The Healthcare Opportunity

China is Australia’s largest trading partner – worth $8.8 billion in 2014-2015. China and Australia are also growing partners in science and research and this is an important area for growth in bilateral relations. China is and has been Australia’s key focus for science and research collaboration efforts; generating advances in medical research, biodiversity, net […]

了解更多

2016年12月26日

Preventing cardiovascular disease through a simple text message

The World Health Organization states that cardiovascular disease (CVD) has been the number one global cause of death; with an estimation of 17.5 million people dying from CVD in 20121, representing 31% of all global deaths. CVD has been and is currently the major cause of death in Australia2 accounting for over 43,600 deaths in […]

了解更多

2016年12月23日

mHealth integration in China

Over the past years, the number of mobile phone subscribers in China has been increasing at an exponential rate. By the end of 2015, there was approximately 202.47 million cell phones produced in China1 along with 1,033.6 million mobile users registered in China, with the number of users expected to grow to 1,086.8 by 2019. […]

了解更多

2016年11月25日

Outsourcing criteria within the Asia-Pacific

乔治临床( George Clinical ) (GC) conducted a brief survey on sponsors who are currently not a customer of GC.  30 companies were surveyed by GC’s Business Development Managers across six cou […]

了解更多

2015年9月3日

Sulfagenix Inc. leverages the R&D Tax Incentive in Australia

Sulfagenix, Inc., a United States based biotech, was able to tap into Australia’s world class research and development (R&D) facilities and expertise […]

了解更多

2015年4月24日

Does air pollution cause COPD?

Chronic obstructive pulmonary disorder (COPD) is now the third most frequent cause of death in the world; however the cause of this disease for a substantial proportion of patients remains unknown.

了解更多

2015年2月25日

Update to Australia’s R&D tax incentive

The R&D Tax Incentive is a targeted, generous and easy to access entitlement program that helps businesses offset some of the costs of doing R&D. The Program aims to help more businesses do R&D and innovate. It is a broad-based entitlement program. This means that it is open to firms of all sizes in all […]

了解更多

2014年6月2日

Australia

乔治临床( George Clinical ) is an Australian owned organization headquartered in Sydney, Australia. In Sydney, we are co-located with our parent organization, The George Institute, a world leading […]

了解更多

2014年5月26日

R&D tax incentives for 乔治临床( George Clinical ) services

There’s no better time to be working with us. The Australian Tax Office will provide a tax incentive to encourage R&D activities in Australia, jointly administered by AusIndustry. Companie […]

了解更多

2013年8月28日

Join Our Mailing List

required
required
required
required
I wish to subscribe to George Clinical communications.
required

在您的网络中添加 乔治临床( George Clinical )